कृपया अन्य खोज का प्रयास करें
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Christopher S. Henney | 81 | 2005 | Independent Director |
David E. Thompson | 74 | 2005 | Independent Director |
Jeffrey Wagener | - | - | Member of Scientific Advisory Board |
David Wofsy | - | 2008 | Member of Scientific Advisory Board |
John Craig Thompson | 55 | 2016 | CEO & Director |
Michael Wilschanski | - | - | Member of Scientific Advisory Board |
Paul F. Truex | 53 | 2004 | Executive Chairman |
Michael W. Konstan | - | - | Member of Scientific Advisory Board |
Joan T. Merrill | - | - | Member of Scientific Advisory Board |
Philip T. Sager | 66 | 2014 | Independent Director |
Jonathan Barratt | - | - | Member of Scientific Advisory Board |
Brent V. Furse | 53 | 2016 | Independent Director |
Kenneth Kalunian | - | 2008 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है